Neurology

If approved, nipocalimab can treat antibody positive individuals with generalized myasthenia gravis.

The pharmacist’s role includes educating and making recommendations, collaborating with health care professionals, and observing early signs of cognitive impairment in patients during interactions.

Duchenne muscular dystrophy is an incurable neuromuscular disorder that can lead to cardiomyopathy, resulting in heart failure.

These inequalities, which can include socioeconomic disparities, show neurological changes associated with aging and dementia.

Researchers recommend early vaccination against herpes zoster to mitigate the risks.

Based on positive results from the HERCULES trial, the new designation will allow for more thorough regulatory review and development of the multiple sclerosis treatment.

Adults with epilepsy are underrepresented in most CBD trials, including common etiologies.

Children born moderate to late preterm also showed more behavior difficulties compared with those born early term or later.

Asthma onset earlier in childhood may be linked to more severe difficulties that could extend to executive function abilities.

Intravenous immunoglobulin (IVIG) has proven efficacy in autoimmune neuropathies, with mixed but promising outcomes in severe COVID-19 cases and post-acute sequelae of SARS-CoV-2 infection trials.

If approved, RAG-21 can offer improved outcomes in patients with amyotrophic lateral sclerosis (ALS), particularly those with aggressive subtypes.

Eladocagene exuparvovec-tneq is the first FDA-approved gene therapy for individuals with aromatic L-amino acid decarboxylase deficiency.

The study found that this patient population was about 25% more likely to have serious mental health issues after childbirth.

If approved, the investigational intravenous gene therapy will be the first disease-modifying therapy for developmental and epileptic encephalopathy (DEE).

The investigators found that the SRGAP2 and SYNGAP1 genes act together to control the speed of human synapse development, which has impacts on neurodevelopmental disease pathways.

Congenital muscular dystrophy type 1a is a severe, early-onset condition that currently has no treatment, but MDL-101 may serve as a 1-time, durable treatment option.

Therapy-related complications, in addition to financial obstacles, can complicate myasthenia gravis treatment.

The diagnostic test is a companion to vorasidenib, an isocitrate dehydrogenase inhibitor that received FDA approval this past summer.

Recognizing repeat dosing efforts is important to improving outcomes in patients with Guillain-Barré syndrome who do not respond to IVIG.

Disruptions in the salience network function are shown to influence the severity of mild behavioral impairment (MBI) symptoms.

Patients aged 7 years and older can now be treated for their cataplexy or excessive daytime sleepiness with the extended-release oral formulation.

This approval makes foscarbidopa/foslevodopa the first and only subcutaneous 24-hour infusion of levodopa-based therapy for adults with Parkinson disease.

Cardiovascular diseases have a significant impact on brain health and function.

High-resolution scans can provide a picture of a patient’s brain that typical MRIs cannot, allowing for more detailed insights into the neurological effects of COVID-19.

Results are promising, particularly because they represent the second clinical trial of a GLP-1 receptor agonist showing potential benefits for PD motor symptoms

Though both treatments come with positives and negatives, ultimately, individual patient clinical presentation and accessibility will determine the proper treatment for myasthenic crisis.

Major biomarkers for cognitive impairment were observed in hospitalized patients with neurological symptoms.

Poor sleep quality is directly related to mortality risk before adjusting for lifestyle or health-related factors, and dementia was noticeably linked to mortality risk in older White males.

Xanomeline and trospium chloride is the first in a new class, offering a new approach with selectively targeting M1 and M4 receptors.

The approval marks the only FDA-approved stand-alone therapy for the treatment of Niemann-Pick disease type C (NPC).